Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: Long-term survival update
Autore:
Atkins, MB; Kunkel, L; Sznol, M; Rosenberg, SA;
Indirizzi:
Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Hematol Oncol,Cytokine Working Grp, Boston, MA 02115 USA Harvard Univ Boston MA USA 02115 tokine Working Grp, Boston, MA 02115 USA CHIRON, Emeryville, CA USA CHIRON Emeryville CA USACHIRON, Emeryville, CA USA Natl Canc Inst, Bethesda, MD USA Natl Canc Inst Bethesda MD USANatl Canc Inst, Bethesda, MD USA
Titolo Testata:
CANCER JOURNAL FROM SCIENTIFIC AMERICAN
, volume: 6, anno: 2000, supplemento:, 1
pagine: S11 - S14
SICI:
1081-4442(200002)6:<S11:HRITIP>2.0.ZU;2-0
Fonte:
ISI
Lingua:
ENG
Soggetto:
RENAL-CELL CARCINOMA; PHASE-I TRIAL; MALIGNANT-MELANOMA; RANDOMIZED TRIAL; COMBINATION; CANCER; RECEPTOR; CHEMOTHERAPY; PREVENTION; CISPLATIN;
Keywords:
immunotherapy; interleukin-2; melanoma;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
33
Recensione:
Indirizzi per estratti:
Indirizzo: Atkins, MB Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Hematol Oncol,Cytokine Working Grp, 330 Brookline Ave E-KS-158, Boston, MA 02115USA Harvard Univ 330 Brookline Ave E-KS-158 Boston MA USA 02115 USA
Citazione:
M.B. Atkins et al., "High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: Long-term survival update", CA J SCI AM, 6, 2000, pp. S11-S14

Abstract

PURPOSETo update response duration and survival data for patients with metastaticmelanoma receiving the high-dose TV bolus recombinant interleukin (IL)-2 regimen. PATIENTS AND METHODSTwo hundred seventy assessable patients were entered into eight clinical trials conducted between 1985 and 1993. IL-2 600,000 or 720,000 IU/kg was administered by 15-minute intravenous infusion every 8 hours for up to 14 consecutive doses over 5 days as clinically tolerated with maximum support, including pressors. A second, identical cycle of treatment was scheduled following 6 to 9 days of rest, and courses could be repeated every 6 to 12 weeks in stable or responding patients. Responding patients received up to fivecourses (two cycles/course) of treatment. All data were updated through December 1998 using report forms completed by the clinical investigators. RESULTSThe objective overall response rate was unchanged from the previous report. Tumor responses were seen in 16% of patients, with complete responses in 17 (6%) and partial responses in 26 (10%). Median survival for the group asa whole is now 12 months. Median follow-up time for surviving patients exceeds 7 years. Median duration of response for the 43 responding patients and the 26 patients with partial responses remained unchanged at 8.9 and 5.9 months, respectively. Response durations ranged from 1.5 to > 122 months. The median duration of complete responses has yet to be reached, but is at least 59 months. Thirty-one patients (11%) were alive as of last contact; 28were confirmed, including 18 responding patients. Three patients were lostto follow-up at > 1, > 13, and > 104 months. Twelve responding patients remained continually disease- or progression-free from > 70 to > 150 months following initiation of therapy. Disease progression was not observed in anypatient who was responding as of the last report or in any patient responding for longer than 30 months. CONCLUSIONThese data continue to support the notion that high-dose IL-2 produces durable responses in some patients with metastatic melanoma and should be considered a therapeutic option for appropriately selected patients with this disease.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/11/20 alle ore 06:58:28